Ligand Pharmaceuticals Incorporated (LGND) Financial Statements
Ligand Pharmaceuticals Incorporated (LGND) reported trailing twelve-month revenue of $290.5M (up 54.9% year on year) and net income of $197.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $131.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 6.1B
- P/E TTM
- 32.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.03 | 0.05 | 0.06 | 0.07 | 0.11 | 0.14 | 0.25 | 0.12 | 0.16 | 0.24 | 0.20 | 0.13 | 0.17 | 0.27 | 0.29 | |
| Gross profit | 0.03 | 0.03 | 0.04 | 0.06 | 0.07 | 0.10 | 0.14 | 0.25 | — | — | — | — | — | — | — | — | |
| Research & development | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.06 | 0.04 | 0.03 | 0.04 | 0.02 | 0.02 | 0.08 | 0.04 | |
| Operating income | -0.00 | 0.00 | 0.01 | 0.02 | 0.03 | 0.04 | 0.07 | 0.16 | 0.81 | 0.04 | 0.10 | 0.00 | 0.01 | -0.02 | 0.04 | 0.09 | |
| Pre-tax income | -0.00 | -0.00 | 0.01 | 0.01 | 0.04 | 0.01 | 0.06 | 0.17 | 0.80 | -0.01 | 0.07 | 0.04 | 0.06 | 0.00 | 0.16 | 0.24 | |
| Income tax | -0.01 | -0.00 | 0.00 | 0.00 | -0.19 | 0.01 | 0.04 | 0.03 | 0.17 | -0.01 | -0.00 | 0.04 | 0.01 | 0.01 | 0.03 | 0.04 | |
| Net income | 0.01 | -0.00 | 0.01 | 0.01 | 0.23 | -0.00 | 0.01 | 0.14 | 0.63 | -0.00 | 0.06 | -0.03 | 0.05 | -0.00 | 0.12 | 0.20 | |
| Diluted EPS ($) | 0.49 | -0.03 | — | 0.56 | 10.83 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 | 9.41 | |
| Diluted shares (bn) | 0.020 | 0.020 | 0.021 | 0.021 | 0.021 | 0.021 | 0.023 | 0.024 | 0.020 | 0.017 | 0.017 | 0.017 | 0.018 | 0.018 | 0.020 | — |
USD billions · SEC XBRL
Ligand Pharmaceuticals Incorporated — questions
- What is Ligand Pharmaceuticals Incorporated's revenue?
- $290.5M over the twelve months to 2026-06-30, up 54.9% year on year, from its 10-Q and 10-K filings.
- What is Ligand Pharmaceuticals Incorporated's net income?
- $197.2M over the twelve months to 2026-06-30.
- What is Ligand Pharmaceuticals Incorporated's free cash flow?
- $131.4M over the twelve months to 2026-06-30.
- What are Ligand Pharmaceuticals Incorporated's diluted earnings per share?
- $9.41 over the twelve months to 2026-06-30.
Every figure on this page comes from Ligand Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.